Patents by Inventor Michael Howard Block

Michael Howard Block has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds effecting glucokinase
    Patent number: 7951830
    Abstract: The invention relates to the use of a compound of Formula (I) or a salt, solvate or prodrug thereof, wherein R1, R2, R3, n and m are as described in the specification, in the preparation of a medicament for the treatment or prevention of a disease condition mediated through glucokinase (GLK), such as type 2 diabetes. The invention also relates to a novel group of compounds of Formula (I) and to methods for preparing compounds of Formula (I).
    Type: Grant
    Filed: February 2, 2009
    Date of Patent: May 31, 2011
    Assignee: AstraZeneca AB
    Inventors: Scott Boyd, Peter William Rodney Caulkett, Rodney Brian Hargreaves, Suzanne Saxon Bowker, Roger James, Clifford David Jones, Darren McKerrecher, Michael Howard Block, Craig Johnstone
  • PYRAZOLE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES
    Publication number: 20100152219
    Abstract: Compounds of formula (I): and their use in the inhibition of Trk activity are described.
    Type: Application
    Filed: February 25, 2010
    Publication date: June 17, 2010
    Applicant: ASTRAZENECA R&D
    Inventors: Michael Howard Block, John W. Lee, David Scott, Haixia Wang, Tao Wang, Dingwei Yu, Yongxin Han, John Anthony Josey, Bin Wang
  • COMPOUNDS EFFECTING GLUCOKINASE
    Publication number: 20090227592
    Abstract: The invention relates to the use of a compound of Formula (I) or a salt, solvate or prodrug thereof, wherein R1, R2, R3, n and m are as described in the specification, in the preparation of a medicament for the treatment or prevention of a disease condition mediated through glucokinase (GLK), such as type 2 diabetes. The invention also relates to a novel group of compounds of Formula (I) and to methods for preparing compounds of Formula (I).
    Type: Application
    Filed: February 2, 2009
    Publication date: September 10, 2009
    Applicant: AstraZeneca AB
    Inventors: Scott BOYD, Peter William Rodney CAULKETT, Rodney Brian HARGREAVES, Suzanne Saxon BOWKER, Roger JAMES, Clifford David JONES, Darren McKERRECHER, Michael Howard BLOCK, Craig JOHNSTONE
  • Compounds effecting glucokinase
    Patent number: 7524957
    Abstract: The invention relates to the use of a compound of Formula (I) or a salt, solvate or prodrug thereof, wherein R1, R2, R3, n and m are as described in the specification, in the preparation of a medicament for the treatment or prevention of a disease condition mediated through glucokinase (GLK), such as type 2 diabetes. The invention also relates to a novel group of compounds of Formula (I) and to methods for preparing compounds of Formula (I).
    Type: Grant
    Filed: February 1, 2008
    Date of Patent: April 28, 2009
    Assignee: AstraZeneca AB
    Inventors: Scott Boyd, Peter William Rodney Caulkett, Rodney Brian Hargreaves, Suzanne Saxon Bowker, Roger James, Clifford David Jones, Darren McKerrecher, Michael Howard Block, Craig Johnstone
  • ENANTIOMERS OF SELECTED FUSED HETEROCYCLICS AND USES THEREOF
    Publication number: 20090099210
    Abstract: This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of cancer.
    Type: Application
    Filed: December 22, 2008
    Publication date: April 16, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Brian Aquila, Michael Howard Block, Audrey Davies, Jayachandran Ezhuthachan, Sandra Ann Filla, Timothy Pontz, Daniel John Russell, Maria-Elena Theoclitou, XiaoLan Zheng
  • Enantiomers of selected fused heterocyclics and uses thereof
    Patent number: 7498333
    Abstract: This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of cancer.
    Type: Grant
    Filed: August 18, 2005
    Date of Patent: March 3, 2009
    Assignee: AstraZeneca AB
    Inventors: Brian Aquila, Michael Howard Block, Audrey Davies, Jayachandran Ezhuthachan, Sandra Ann Filla, Timothy Pontz, Daniel John Russell, Maria-Elena Theoclitou, XiaoLan Zheng
  • Enantiomers of Selected Fused Pyrimidones and Uses in the Treatment and Prevention of Cancer
    Publication number: 20080293744
    Abstract: This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of cancer.
    Type: Application
    Filed: August 16, 2005
    Publication date: November 27, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Brian Aquila, Michael Howard Block, Audrey Davies, Jayachandran Ezhuthachan, Timothy Pontz, Daniel John Russell, Marie-Elena Theoclitou, XiaoLan Zheng
  • Compounds Effecting Glucokinase
    Publication number: 20080207636
    Abstract: The invention relates to the use of a compound of Formula (I) or a salt, solvate or prodrug thereof, wherein R1, R2, R3, n and m are as described in the specification, in the preparation of a medicament for the treatment or prevention of a disease condition mediated through glucokinase (GLK), such as type 2 diabetes. The invention also relates to a novel group of compounds of Formula (I) and to methods for preparing compounds of Formula (I).
    Type: Application
    Filed: February 1, 2008
    Publication date: August 28, 2008
    Applicant: AstraZeneca AB
    Inventors: Scott Boyd, Peter William Rodney Caulkett, Rodney Brian Hargreaves, Suzanne Saxon Bowker, Roger James, Clifford David Jones, Darren McKerrecher, Michael Howard Block, Craig Johnstone
  • Carbazole derivatives and their use as NPY5 receptor antagonists
    Patent number: 7408064
    Abstract: The use of a compound of formula (I) in the manufacture of a medicament for the treatment, in a warm-blooded animal, of disorders mediated by the neuropeptide Y5 receptor: wherein: R1, R2, R3 and X1-X6 are as defined within or a pharmaceutically acceptable salt, prodrug or solvate thereof, is described. Pharmaceutical compositions, methods and processes for preparation of compounds of formula (I) are also described.
    Type: Grant
    Filed: September 9, 2002
    Date of Patent: August 5, 2008
    Assignee: AstraZeneca AB
    Inventors: Kevin Michael Foote, Michael Howard Block, Wayne Brailsford
  • NOVEL FUSED HETEROCYCLES AND USES THEREOF
    Publication number: 20080153854
    Abstract: This invention relates to novel compounds having the formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined in the specification and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of cancer.
    Type: Application
    Filed: February 15, 2008
    Publication date: June 26, 2008
    Applicant: AstraZeneca AB
    Inventors: Brian Aquila, Michael Howard Block, Audrey Davies, Jayachandran Ezhuthachan, Sandra Filla, Richard William Luke, Timothy Pontz, Daniel John Russell, Maria-Elena Theoclitou, XiaoLan Zheng
  • Compounds effecting glucokinase
    Patent number: 7390908
    Abstract: The invention relates to the use of a compound of Formula (I) or a salt, solvate or prodrug thereof, wherein R1, R2, R3, n and m are as described in the specification, in the preparation of a medicament for the treatment or prevention of a disease condition mediated through glucokinase (GLK), such as type 2 diabetes. The invention also relates to a novel group of compounds of Formula (I) and to methods for preparing compounds of Formula (I).
    Type: Grant
    Filed: August 15, 2002
    Date of Patent: June 24, 2008
    Assignee: AstraZeneca AB
    Inventors: Scott Boyd, Peter William Rodney Caulkett, Rodney Brian Hargreaves, Suzanne Saxon Bowker, Roger James, Craig Johnstone, Clifford David Jones, Darren McKerrecher, Michael Howard Block
  • Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor
    Patent number: 7332492
    Abstract: Compounds of formula (I): wherein: X is a group of formula (B): and R1, R2, R4, n, x, y and z are as defined within are described. Processes for their preparation and their use in the treatment of disorders mediated by the neuropeptide Y5 receptor in a warm-blooded animal, such as a human being, are also described.
    Type: Grant
    Filed: May 12, 2005
    Date of Patent: February 19, 2008
    Assignee: AstraZeneca AB
    Inventors: Michael Howard Block, Kevin Michael Foote
  • Enantiomers of selected fused heterocyclics and uses thereof
    Publication number: 20060041129
    Abstract: This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of cancer.
    Type: Application
    Filed: August 18, 2005
    Publication date: February 23, 2006
    Applicant: AstraZeneca AB
    Inventors: Brian Aquila, Michael Howard Block, Audrey Davies, Jayachandran Ezhuthachan, Timothy Pontz, Daniel John Russell, Maria-Elena Theoclitou, XiaoLan Zheng
  • Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor
    Patent number: 6967216
    Abstract: Compounds of formula (I): wherein: X is a group of formula (A) or (B): and R1, R2, R3, R4, n, x, y and z are as defined within are described. Processes for their preparation and their use in the treatment of disorders mediated by the neuropeptide Y5 receptor in a warm-blooded animal, such as a human being are also described.
    Type: Grant
    Filed: May 1, 2001
    Date of Patent: November 22, 2005
    Assignee: AstraZeneca AB
    Inventors: Michael Howard Block, Craig Samuel Donald, David Robert Brittain, Kevin Michael Foote
  • Amides as inhibitors for pyruvate dehydrogenase
    Patent number: 6878712
    Abstract: A compound of formula (I): wherein: Ring A is a nitrogen linked mono or bicyclic heterocyclic ring as defined within; R1 and R2 are independently C1-3alkyl optionally substituted by fluoro or chloro; or R1 and R2 together with the carbon atom to which they are attached, form a C3-5cycloalkyl ring optionally substituted by fluoro; R3 is defined within; and n is 0-5; wherein the values of R3 may be the same or different; or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof is described. The use of compounds of formula (I) in the production of an elevation of PDH activity in a warm-blooded animal such as a human being are also described. Pharmaceutical compositions, methods and processes for preparation of compounds of formula (I) are detailed.
    Type: Grant
    Filed: August 30, 2000
    Date of Patent: April 12, 2005
    Assignee: AstraZeneca AB
    Inventors: Roger John Butlin, Janet Elizabeth Pease, Michael Howard Block, Thorsten Nowak, Jeremy Nicholas Burrows, David Stephen Clarke
  • Carbazole derivatives and their use as neuropeptide y5 receptor ligands
    Publication number: 20040067999
    Abstract: Compounds of formula (I): are described wherein R1-R6 and m are as defined within. Processes for their preparation and their use as NPY 5 inhibitors is described.
    Type: Application
    Filed: October 10, 2003
    Publication date: April 8, 2004
    Inventors: Michael Howard Block, Kevin Michael Foote, Craig Samuel Donald, Paul Schofield
  • Substituted N-phenyl 2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivatives which elevate pyruvate dehydrogenase activity
    Patent number: 6689909
    Abstract: A compound of formula (I) wherein: n is 1 or 2; R1 is chloro, fluoro, bromo, methyl or methoxy; R2 is as defined within; R3 is as defined within; and R4 is hydrogen or fluoro; or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof is described. The use of compounds of formula (I) in the production of an elevation of PDH activity in a warm-blooded animal such as a human being are also described. Pharmaceutical compositions, methods and processes for preparation of compounds of formula (I) are detailed.
    Type: Grant
    Filed: June 17, 2002
    Date of Patent: February 10, 2004
    Assignee: AstraZeneca AB
    Inventors: Roger John Butlin, Janet Elizabeth Pease, Michael Howard Block, Thorsten Nowak, Jeremy Nicholas Burrows
  • Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor
    Publication number: 20030225097
    Abstract: Compounds of formula (I): 1
    Type: Application
    Filed: November 5, 2002
    Publication date: December 4, 2003
    Inventors: Michael Howard Block, Craig Samuel Donald, David Robert Brittain, Kevin Michael Foote
  • Chemical compounds
    Patent number: 6552225
    Abstract: A compound of formula (I) wherein: R1, R2, R3, R4, R5, R6 and R7 are as defined within; or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof is described. The use of compounds of formula (I) in the production of an elevation of PDH activity in a warm-blooded animal such as a human being are also described. Pharmaceutical compositions, methods and processes for preparation of compounds of formula (I) are detailed.
    Type: Grant
    Filed: June 17, 2002
    Date of Patent: April 22, 2003
    Assignee: AstraZeneca AB
    Inventors: Roger John Butlin, Janet Elizabeth Pease, Michael Howard Block, Thorsten Nowak, Jeremy Nicholas Burrows